## Adzenys XR-ODT®
**Effective March 1, 2018**

<table>
<thead>
<tr>
<th>Plan</th>
<th>Program Type</th>
</tr>
</thead>
<tbody>
<tr>
<td>☒ MassHealth</td>
<td>☒ Prior Authorization</td>
</tr>
<tr>
<td>☐ Commercial/Exchange</td>
<td>☐ Quantity Limit</td>
</tr>
<tr>
<td>☐ ☐ Commercial/Exchange</td>
<td>☐ Step Therapy</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Benefit</th>
<th>N/A</th>
<th>N/A</th>
</tr>
</thead>
<tbody>
<tr>
<td>☒ Pharmacy Benefit</td>
<td>☐ Medical Benefit (NLX)</td>
<td>☐ Non-Specialty Medications</td>
</tr>
</tbody>
</table>

### Specialty Limitations
- N/A

### Specialty Medications
- All Plans: Phone: 866-814-5506 | Fax: 866-249-6155

### Non-Specialty Medications
- MassHealth: Phone: 877-433-7643 | Fax: 866-255-7569
- Commercial: Phone: 800-294-5979 | Fax: 888-836-0730
- Exchange: Phone: 855-582-2022 | Fax: 855-245-2134

### Medical Specialty Medications (NLX)
- All Plans: Phone: 844-345-2803 | Fax: 844-851-0882

### Contact Information

<table>
<thead>
<tr>
<th>Plan</th>
<th>Specialties</th>
<th>Phone</th>
<th>Fax</th>
</tr>
</thead>
<tbody>
<tr>
<td>MassHealth</td>
<td>All Plans</td>
<td>866-814-5506</td>
<td>866-249-6155</td>
</tr>
<tr>
<td>Commercial</td>
<td></td>
<td>800-294-5979</td>
<td>888-836-0730</td>
</tr>
<tr>
<td>Exchange</td>
<td></td>
<td>855-582-2022</td>
<td>855-245-2134</td>
</tr>
<tr>
<td>MassHealth</td>
<td>Medical Specialty Medications (NLX)</td>
<td>844-345-2803</td>
<td>844-851-0882</td>
</tr>
</tbody>
</table>

### Exceptions
- N/A

### Overview
Adzenys XR-ODT is a central nervous system (CNS) stimulant indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in patients 6 years and older.

### Coverage Guidelines
1. Member has a diagnosis of attention deficit hyperactivity disorder (ADHD) or autism spectrum disorder (ASD) or narcolepsy AND
2. Prescriber has provided documentation of an inadequate response, adverse reaction, or contraindication to Adderall XR® (amphetamine salts extended-release)

*Please note: Additional criteria may apply for members under the age of 18. Please refer to the MassHealth Pediatric Behavioral Health Medication Initiative guideline for criteria.*

### Continuation of Therapy
Reauthorization require documentation by prescriber that indicates a positive response to therapy.

### Limitations
Initial and reauthorization approvals may be granted for up to 1 year

### Appendix
Adverse reactions/contraindications to stimulants include but are not limited to weight loss or failure to gain weight, insomnia, agitation, increased anger and aggression, tic disorder, seizures w/ ADHD, traumatic brain injury w/ ADHD (trial of both a methylphenidate product and amphetamine product is required for approval), symptomatic heart disease in children (tachycardia or hypertension), symptomatic

---

399 Revolution Drive, Suite 810, Somerville, MA 02145 | allwayshealthpartners.org

AllWays Health Partners includes AllWays Health Partners, Inc. and AllWays Health Partners Insurance Company
heart disease in adults (there should be at least 1 failed trial of another non-stimulant medication that may be used for ADHD such as bupropion.)

References
1. Adzenys XR-ODT (amphetamine) [prescribing information]. Grand Prairie, TX: Neos Therapeutics Brands LLC.; December 2017

Review History
03/01/18 – Implemented (Adopted MH PDS)
04/17/19 – Reviewed P&T Mtg

Disclaimer
AllWays Health Partners complies with applicable federal civil rights laws and does not discriminate or exclude people on the basis of race, color, national origin, age, disability, or sex.